Semaglutide-d8 is the deuterium-labeled form of Semaglutide. Semaglutide, a long-acting, selective, competitive GLP-1R agonist, can cross the blood-brain barrier. Upon GLP-1R activation, it promotes insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while suppressing oxidative stress and apoptosis. It also regulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide exhibits activities like lowering blood glucose, weight reduction, neuroprotection (e.g., improving motor function in Parkinson’s models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is used in the research of type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative diseases, liver disorders, and cancer.

司美格鲁肽-d8